May 2023
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias
Register to attend a free NIH webinar. Attendees will learn about a new T-cell receptor (TCR) that targets CD22, being developed by the National Cancer Institute (NCI) as a cellular immunotherapy to treat lymphomas and leukemias. CD22 TCR-T cells clear leukemia at clinically relevant doses without causing systemic cytokine elevation. The webinar will highlight: Novel CD22 specific TCR-T cells reducing tumor burden at clinically relevant doses A new therapeutic method using these novel CD22 specific TCR-T cells that overcomes current…
Find out more »October 2023
NCI Technology Opportunity Webinar: Anti-EGFR Antibodies for the Treatment of Human Cancers
Register to attend a free NIH webinar. Attendees will learn about new antibodies developed in Dr. David Fitzgerald’s Lab that bind a particular structure on the external domain of epidermal growth factor receptor (EGFR) which is displayed on cancer cells that express high EGFR levels or the variant termed ‘EGFRvIII’. Importantly, these antibodies do not bind normal cells. Therefore, these antibodies are used to deliver toxic payloads (as antibody-drug conjugates - ADCs) to cancer cells without killing normal cells. Additionally,…
Find out more »